Literature DB >> 31501150

Electronic Cigarette Use among Survivors of Smoking-Related Cancers in the United States.

Oladimeji Akinboro1, Stanley Nwabudike2, Rawad Elias3, Oluseyi Balasire4, Olatunde Ola5, Jamie S Ostroff6.   

Abstract

BACKGROUND: The prevalence of electronic cigarette (e-cigarette) use and its impact on smoking cessation among cancer survivors in the United States is largely unknown. We sought to estimate the prevalence of e-cigarette use and examine its associations with cigarette smoking and smoking quit attempts among smoking-related cancer survivors in the United States.
METHODS: We obtained data from the 2014-2017 annual cycles of the National Health Interview Survey for participants with self-reported history of smoking-related cancer(s). We calculated the prevalence of current e-cigarette use and utilized multinomial logistic regression in examining the independent association between e-cigarette use and cigarette smoking. Appropriate survey weights were applied in estimating the prevalence rates, relative risk ratios (RRR), ORs, and confidence intervals (CI).
RESULTS: Our sample comprised 3,162 smoking-related cancer survivors. The prevalence of current e-cigarette use was 3.18% (95% CI, 2.40-3.96). Current e-cigarette users were 83 times as likely as never users to be current cigarette smokers (RRR, 82.89; 95% CI, 16.54-415.37). Among those with a history of cigarette smoking, current e-cigarette users were 90% less likely to be former smokers (OR, 0.10; 95% CI, 0.05-0.18). No association was seen between current e-cigarette use and a smoking quit attempt in the prior year.
CONCLUSIONS: E-cigarette use among cigarette ever smokers was associated with a lower likelihood of being a former smoker/having quit smoking, and e-cigarette use was not associated with smoking quit attempts. IMPACT: Our findings do not provide evidence that e-cigarette use facilitates smoking cessation among smoking-related cancer survivors. ©2019 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2019        PMID: 31501150     DOI: 10.1158/1055-9965.EPI-19-0105

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.090


  5 in total

1.  Nicotine, smoking, podocytes, and diabetic nephropathy.

Authors:  Edgar A Jaimes; Ming-Sheng Zhou; Mohammed Siddiqui; Gabriel Rezonzew; Runxia Tian; Surya V Seshan; Alecia N Muwonge; Nicholas J Wong; Evren U Azeloglu; Alessia Fornoni; Sandra Merscher; Leopoldo Raij
Journal:  Am J Physiol Renal Physiol       Date:  2021-01-18

2.  Longitudinal Electronic Cigarette Use Among Patients Recently Diagnosed With Cancer Enrolled in a Smoking Cessation Trial.

Authors:  Sara Kalkhoran; Joanna M Streck; Gina R Kruse; Nancy A Rigotti; Giselle K Perez; Susan Regan; Colin J Ponzani; Alona Muzikansky; Elyse R Park; Jamie S Ostroff
Journal:  Nicotine Tob Res       Date:  2022-06-15       Impact factor: 5.825

3.  A descriptive study of cervical cancer survivors' persistent smoking behavior and perceived barriers to quitting.

Authors:  Tia N Borger; Gabriella E Puleo; Jessica N Rivera Rivera; Devin Montgomery; William R Bowling; Jessica L Burris
Journal:  Psychol Addict Behav       Date:  2021-03-25

4.  Feasibility of Patient Navigation-Based Smoking Cessation Program in Cancer Patients.

Authors:  Tongyao Fan; Jessica M Yingst; Rebecca Bascom; Leonard Tuanquin; Susan Veldheer; Steven Branstetter; Jonathan Foulds; Joshua E Muscat
Journal:  Int J Environ Res Public Health       Date:  2022-03-29       Impact factor: 3.390

5.  Tobacco Use and Tobacco Treatment Referral Response of Patients With Cancer: Implementation Outcomes at a National Cancer Institute-Designated Cancer Center.

Authors:  Jessica L Burris; Tia N Borger; Brent J Shelton; Audrey K Darville; Jamie L Studts; Joseph Valentino; Courtney Blair; D Bront Davis; Joan Scales
Journal:  JCO Oncol Pract       Date:  2021-06-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.